Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma Clinical Trial

Official title:

TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00139230
• Other study ID #: 96-184
• Status: Completed
• Phase: Phase 2
• First received: August 29, 2005
• Last updated: June 2, 2008
• Start date: January 1997
• Est. completion date: December 2006

Study information

• Verified date: June 2008
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.

Description:

• Patients will be admitted to hospital and receive a one hour infusion of taxotere. Approximately 2 hours after taxotere is finished they will receive cisplatin, 5-fluorouracil, and leucovorin continuously over a 4 day period.

• Approximately 6-12 hours after the chemotherapy ends patients will be given growth factor support and ciprofloxacin until the patient's ANC level is greater than 10,000.

• Infusion of chemotherapy will be repeated every 28 days (1 cycle is 28 days).

• During each cycle patients will have blood tests performed weekly and may be asked to return to the Head and Neck Clinic for examination around the middle of each cycle.

• At the end of each cycle the impact of the chemotherapy will be assessed. If after 2 cycles, the cancer has not responded sufficiently the patient will not receive any more chemotherapy. However, if significant reduction in the size of the patients tumor is observed, a third and final cycle will be performed.

• During the fourth or fifth week of cycle 3, patients will undergo re-staging evaluation under anesthesia with primary-site biopsies and planning of radiotherapy.

• Within 2 weeks of completion of chemotherapy cycle 3 all patients will receive twice daily radiotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic confirmation of squamous cell carcinoma of head and neck.

• All patients with previously untreated Stage III or IV.

• Measurable disease

• Complete recovery from previous diagnostic or therapeutic procedures.

• Life expectancy greater than 3 months

• Creatinine less than or equal to 1.5

• SGOT less than 1.5 x ULN

• Alkaline phosphatase less than 2.5 x ULN

• WBC greater than or equal to 4,000/mm

• Platelet count greater than to equal to 100,000/mm

• Hemoglobin greater than or equal to 10gm/dl

• Patients of childbearing age must use effective contraception methods.

Exclusion Criteria:

• Patients with previous head and neck cancer except those treated with surgery only.

• Patients with concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

• Peripheral neuropathy exceeding grade 1.

• Cardiovascular or pulmonary disease

• Pregnant or breastfeeding women

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma of Head/Neck
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma

Intervention

Drug:
• Taxotere

• Cisplatin

• 5-Fluorouracil

• Leucovorin

• G-CSF

• Ciprofloxacin

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Brigham and Women's Hospital, Massachusetts General Hospital, Sanofi

Country where clinical trial is conducted

United States, 

References & Publications (4)

Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S, Posner MR. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002 Apr;25(2):153-9. — View Citation

Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31. — View Citation

Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15;97(2):412-8. — View Citation

Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):678-81. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety of a four day regimen of taxotere, cisplatin, 5-fluorouracil and high-dose leucovorin with growth factor support and ciprofloxacin.
Secondary	To determine the efficacy of this regimen in patients with advances, previously untreated squamous cell carcinoma of the head and neck.